Effect of Potato Fiber on Appetite and Fecal Fat Excretion (POFIBA)

Results have indicated that some dietary fibers increase fecal fat excretion and particularly viscous fibers suppress appetite sensation and reduce energy intake. Both these effects may contribute to body weight management.

Aim: The aim of the study is to investigate the potential of 3-weeks daily intake of potato pulp (FiberBind), rhamnogalacturonan I isolated potato fiber (RG-I) vs. a low-fiber control (placebo) on satiety and fecal fat excretion in healthy adults. Furthermore, a number of secondary endpoints are investigated.

Study Overview

• Status: Completed
• Conditions: Obesity; Appetite; Fecal Fat Increased
• Intervention / Treatment: Dietary supplement: FiberBind; Dietary supplement: RG-I fiber; Dietary supplement: Placebo

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Denmark
  • Copenhagen, Denmark, 1958
    • University of Copenhagen, Department of Nutrition, Exercise and Sports

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 40 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Healthy Men
• BMI between 18.5 and 27.0 kg/m2
• Age 20-40 years

Exclusion Criteria:

• Intake of potatoes with main meals more frequent than 4 times per week
• Chronic diseases (known diabetes, cardiovascular disease, irritable bowels disease, colitis ulcerosa, crohn disease, or other chronic diseases which could affect the results of the present study)
• Gluten allergy
• Use of daily prescription medicine (mild analgesics are allowed)
• Use of lipid-lowering agents (e.g. Becel, HUSK)
• Use of food supplements of relevance to the study (such as pre- and probiotics)
• Irregular intake of vitamin /mineral supplements (two weeks prior to and during the entire study period)
• Smoking
• Elite athletes (>10 hours of strenuous physical activity per week)
• Blood donation (<1 month before study commencement and during study period)
• Participation in other clinical studies (<1 month before study commencement and during study period)
• Inability (physically or psychologically) to comply with the procedures required by the protocol judged by the Investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Dietary supplement: Placebo; Low-fiber control
Experimental: FiberBind	Dietary supplement: FiberBind; Potato pulp consisting of 68% fiber (5.5 soluble, 76.7% insoluble and 17.8% resistant starch), 9.7% water, 0.3% fat, 7.2% protein and 14% carbohydrates (starch).
Experimental: RG-I fiber	Dietary supplement: RG-I fiber; Soluble fiber extracted from potato pulp consisting of 95% fiber and 5% water.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Fecal fat excretion		Based on total feces collection the last 3 days of the 21-day intervention periods
Subjective appetite sensations	Assessed by visual analogue scales (VAS)	Assessed on 3-hour meal test on last day of the 21-day intervention periods

Secondary Outcome Measures

Outcome Measure	Time Frame
Ad libitum energy intake	Assessed 3 hours after intake of the test meal on last day of the 21-day intervention periods
Fecal energy excretion	Measured based on total feces collection the last 3 days of the 21-day intervention periods
Blood lipids (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides)	Measured before and after the 21-day intervention periods
Insulin and glucose	Measured before and after the 21-day intervention periods, and every 30 minutes during the 3-hour meal test on last day of the 21-week intervention periods
Gut permeability marker	Measured before and after the 21-day intervention periods
Gastric emptying rate (w. paracetamol)	Measured every 30 minutes during the 3-hour meal test on last day of the 21-day intervention periods
Gastrointestinal symptoms (questionnaire)	on day 1, 7, 14 and 22 of the 21-day intervention periods
Body weight	up to 21-day intervention periods
Blood pressure	up to 21-day intervention periods
Breath hydrogen	up to 21-day intervention periods
Gut microbiota	Measured in a fresh feces sample from day 19-21 of the intervention periods

Collaborators and Investigators

• Sponsor: University of Copenhagen

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2016
• Primary Completion (Actual): March 31, 2017
• Study Completion (Actual): March 31, 2017

Study Registration Dates

• First Submitted: November 1, 2016
• First Submitted That Met QC Criteria: November 4, 2016
• First Posted (Estimate): November 6, 2016

Study Record Updates

• Last Update Posted (Actual): September 13, 2017
• Last Update Submitted That Met QC Criteria: September 12, 2017
• Last Verified: May 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Metabolic Diseases; Gastrointestinal Diseases; Intestinal Diseases; Malabsorption Syndromes; Steatorrhea
• Other Study ID Numbers: B 326